Filtered By:
Specialty: Drugs & Pharmacology
Management: Contracts
This page shows you your search results in order of date.
Order by Relevance | Date
Total 1 results found since Jan 2013.
Upregulation of wild-type p53 by small molecule-induced elevation of NQO1 in non-small cell lung cancer cells
Acta Pharmacol Sin. 2021 May 25. doi: 10.1038/s41401-021-00691-8. Online ahead of print.ABSTRACTThe tumor suppressor p53 is usually inactivated by somatic mutations in malignant neoplasms, and its reactivation represents an attractive therapeutic strategy for cancers. Here, we reported that a new quinolone compound RYL-687 significantly inhibited non-small cell lung cancer (NSCLC) cells which express wild type (wt) p53, in contract to its much weaker cytotoxicity on cells with mutant p53. RYL-687 upregulated p53 in cells with wt but not mutant p53, and ectopic expression of wt p53 significantly enhanced the anti-NSCLC acti...
Source: Acta Pharmacologica Sinica - May 26, 2021 Category: Drugs & Pharmacology Authors: Hong Yu Hong-Ying Gao Hua Guo Gui-Zhen Wang Yi-Qing Yang Qian Hu Li-Jun Liang Qun Zhao Da-Wei Xie Yu Rao Guang-Biao Zhou Source Type: research
